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ABSTRACT
HBP1 is a sequence-specific DNA-binding transcrip-
tion factor with many important biological roles. It
activates or represses the expression of some spe-
cific genes during cell growth and differentiation.
Previous studies have exhibited that HBP1 binds to
p16
INK4A promoter and activates p16
INK4A expres-
sion. We found that trichostatin A (TSA), an inhibitor
of HDAC (histone deacetylase), induces p16
INK4A ex-
pression in an HBP1-dependent manner. This result
was drawn from a transactivation experiment by
measuring relative luciferase activities of p16
INK4A
promoter with HBP1-binding site in comparison
with that of the wild-type p16
INK4A promoter by tran-
sient cotransfection with HBP1 into HEK293T cells
and 2BS cells. HBP1 acetylation after TSA treatment
was confirmed by immunoprecipitation assay. Our
data showed that HBP1 interacted with histone
acetyltransferase p300 and CREB-binding protein
(CBP) and also recruited p300/CBP to p16
INK4A
promoter. HBP1 was acetylated by p300/CBP in
two regions: repression domain (K297/305/307) and
P domain (K171/419). Acetylation of Repression
domain was not required for HBP1 transactivation on
p16
INK4A. However, luciferase assay and western
blotting results indicate that acetylation of P
domain, especially K419 acetylation is essential for
HBP1 transactivation on p16
INK4A. As assayed by
SA-beta-gal staining, the acetylation of HBP1 at
K419 enhanced HBP1-induced premature senes-
cence in 2BS cells. In addition, HDAC4 repressed
HBP1-induced premature senescence through per-
manently deacetylating HBP1. We conclude that
our data suggest that HBP1 acetylation at K419
plays an important role in HBP1-induced p16
INK4A
expression.
INTRODUCTION
HBP1 is homologous to the sequence-speciﬁc high
mobility group (HMG) family of transcription factors
(1,2). We have previously isolated HBP1 as a retinoblast-
oma (RB) partner and have determined that it functions as
a proliferation regulator by inhibiting oncogenic pathways
as a transcriptional repressor (3–8). Recently, the HBP1
transcriptional repressor has been reported as a putative
substrate for the p38 MAPK in cell-cycle arrest (9).
Mechanistically, p38 MAPK-mediated phosphorylation
of the HBP1 leads to increased protein stability and G1
arrest. A speciﬁc p38 MAPK phosphorylation site (serine
401) has been identiﬁed in the HBP1 protein. Moreover,
our previous work demonstrated that HBP1 is necessary
for premature senescence induced by Ras-p38 MAPK
(10). Furthermore, HBP1 itself also induces premature
senescence through upregulating p16
INK4A expression in
primary cells (18). p16
INK4A knockdown can abolish
HBP1- and Ras-induced premature senescence. Together,
our previous data support a model in which HBP1 is a
downstream effector of Ras, and p38 MAPK, and
provide new insights into the signaling mechanisms that
lead to premature senescence. All of the data indicate
that HBP1 modulation is a complex process, and the bio-
logical consequences of HBP1 activation induced by
certain stimuli may depend on HBP1 post-translational
modiﬁcation at multiple sites. There is no report about
the roles of the acetylated HBP1. Investigating whether
or not HBP1 is acetylated by acetyltransferase and if the
acetylated HBP1 increases its DNA binding as well as
downstream transcriptional activity are the objectives of
this report.
Histone deacetylase (HDAC) inhibitors have been ex-
tensively studied in basic biological research to gain an
understanding of basic chromatin structure and transcrip-
tional control and have recently been introduced as poten-
tial clinical treatment for cancer (11–15). Generally,
HDAC inhibitors induce accumulation of hyperacety-
lated nucleosome core histones and cause transcriptional
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are reported to increase acetylation of non-histone proteins
(16,17). The common laboratory HDAC inhibitor tri-
chostatin A (TSA) is a potential candidate for the study
of HBP1 acetylation.
In this study, normal human lung ﬁbroblast 2BS cells
were treated with TSA to test changes of HBP1 acetyl-
ation. When assayed for relative luciferase activity using
mutagenized p16
INK4A promoters and transfection of
wild-type HBP1 into 2BS cells, TSA-induced p16
INK4A
expression was partially attributed to HBP1 acetylation.
Furthermore, HBP1 interacted with both histone acetyl-
transferase p300 and CREB-binding protein (CBP). HBP1
was acetylated by p300/CBP at speciﬁc sites: the
Repression domain (K297/305/307) and the P domain
(K171/419). The acetylation of K419 within the P
domain is essential for HBP1 transcriptional activation
on p16
INK4A by increasing its DNA binding to the
p16
INK4A promoter.
MATERIALS AND METHODS
Cell culture, transfection and treatment
Human lung ﬁbroblasts 2BS (27,28), Human embryonic
kidney HEK293T cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (Gibco) supplemented with
10% fetal bovine serum, 100units/ml penicillin and
100mg/ml streptomycin, at 37 Ci n5 %C O 2. All the plas-
mids were transfected into cells using Lipofectamine 2000
(Invitrogen) following the manufacturer’s protocol. The
cells were collected at 24 to 48h after transfection for fur-
ther analysis. The HDAC inhibitor Trichostatin A (TSA)
(Sigma) was dissolved in ethanol and added into culture
medium at 1 or 2mM for 12 to 24h. The control cells were
treated with an equal volume of ethanol for the same time
periods as mentioned above.
Expression and knockdown plasmids
The overexpression vectors of HBP1 and its point mutants
K171R, K419R, K171R/K419R were constructed in the
pcDNA3.1 background. The point mutations were intro-
duced at positions 171aa, 419aa, 171aa and 419aa by
changing Lysine (K, AAA or AAG) into Arginine
(R, AGA or AGG) with overlap PCR. All the plasmids
were transfected into cells using Lipofectamine 2000 for
transient expression. To obtain stable expression cell lines,
cells were infected using lentiviral gene expression system.
To prepare lentiviral particles, HEK293T cells were trans-
fected with the three packaging plasmids of pLP1, pLP2
and pLP3 and one expression plasmid of pITA inserted
with the gene of interest. The supernatant was harvested
and added to the culture medium of target cells for 8–12h.
Then the cells were selected by puromycin and these cells
were further used in later experiments. The short hairpin
RNA (shRNA) plasmid targeting 19 residues for human
HBP1 or HDAC4 was constructed in the pSuper-retro
background: HBP1 knockdown (GATCCCCACTGTGA
GTGCCACTTCTCTTCAAGAGAGAGAAGTGGCAC
TCACAGTTTTTTGGAAA), HDAC4 knockdown (GA
TCCCCGTCGGGCCAGTGGTCACTGTTCAAGAGA
CAGTGACCACTGGCCCGACTTTTTGGAAA). The
underlined sequences represent the hairpin (10). The
plasmids were transfected into cells by using
Lipofectamine 2000 according to the manufacturer’s in-
struction. For the p300/CBP knockdown, cells were trans-
fected with p300 siRNA (AACAGAGCAGUCCUGGA
UUAG) and CBP siRNA (UAGUAACUCUGGCCAUA
GC) using oligofectamine reagent (Invitrogen) according
to the manufacturer’s instructions.
RT–PCR
Total RNA was isolated using the RNeasy Mini Kit
(Qiagen) following the manufacturer’s protocol. One
microgram of RNA was analyzed by reverse transcription
(RT)–PCR with the Access RT–PCR Kit (Promega). The
DNA sequences of the human HBP1 primers (10) were
50-ATCATCTCCTGTACACATCATAGC-30 and 50-CA
TAGAAAGGGTGGTCCAGCTTAC-30. These primers
resulted in an RT–PCR product of 523bp. The DNA se-
quences of the human p16
INK4A primers were 50-GCCGG
CGGCGGGGAGCAGCATGG-30 and 50-CAGCATTC
GAGAGATCTGTACGC-30. These primers resulted in
an RT–PCR product of 379bp. The DNA sequences of
the human GAPDH primers were 50-CGAGTCAACGGA
TTTGGTGGTAT-30 and 50-AGCCTTCTCCATGGTGA
AGAC-30. These primers resulted in an RT–PCR product
of 320bp. GAPDH was applied as internal control for
normalizing the RT–PCR results.
Immunoblotting and antibody
The cells were collected and lysed in cell lysis buffer
(50mM Tris–HCl, pH 7.4, 1% NP-40, 0.25% sodium
deoxycholate, 150mM NaCl, 1mM EGTA, 1mM
Na3VO4, 1mM NaF) containing protease inhibitors:
1mM PMSF (Sigma), 1mg/ml Leupeptin (Sigma) and
1mg/ml Pepstatin A (Sigma). After the insoluble part of
the lysates was cleared by centrifugation, protein concen-
trations were determined by the BCA Protein Assay Kit
(Pierce). Forty micrograms of proteins were separated by
sodium dodecyl sulfate–polyacrylamide gel electrophor-
esis (SDS–PAGE) and transferred onto a nitrocellulose
(NC) membrane. The primary antibodies used for
western blot analysis were against HBP1 (N-20X, Santa
Cruz), HBP1 (ab83402, Abcam), p16
INK4A (C-20, Santa
Cruz), p38 (A-12, Santa Cruz), HA.11 antibody
(Convance), Flag (Sigma), p300 (sc-585, Santa Cruz),
CBP (sc-369, Santa Cruz), PCAF (sc-8999, Santa Cruz),
GST (M071-3, MBL) and Anti-Multi Ubiquitin (D058-3,
MBL) and Acetylated-Lysine Monoclonal Antibody
(#9681, CST).
Immunoprecipitation
Cells were lysed in cell lysis buffer containing protease
inhibitors and incubated on ice for 20min. Extracts were
cleared by centrifugation at 12000rpm for 10min at 4 C.
Supernatants were subjected to immunoprecipitation with
the speciﬁc antibodies by rocking for 1h at 4 C followed
by the addition of 40ml of a 50% slurry of protein A
agarose beads (Sigma) and further incubation for 1h.
Precipitated complexes were pelleted, washed three times
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fer for 5min. The supernatants were transferred to new
tubes for further western blot analysis.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assay was per-
formed using the Chromatin Immunoprecipitation Assay
Kit (Upstate) following the manufacturer’s instruction
with slight modiﬁcation. For the p16
INK4A promoter, the
PCR product to be ampliﬁed resides at the position of
 272 to  699bp. The sequences of PCR primers were
50-CCTTCCAATGACTCCCTC-30 and 50-AACCTTCC
TAACTGCCAAA-30. The HBP1-binding site is located
in the region from  426 to  433bp of the p16
INK4A
promoter (11).
Puriﬁcation of recombinant proteins
The glutathione S-transferase (GST) fusion protein ex-
pression vectors of p53, HBP1 and its mutants
DelHMG, DelRepression, Repression, HMG, P, P1, P2,
P3, P2-K144, P2-K160, P2-K 171, P3-K416, P3-K419
were inserted into the basic pGEX-4T-1 vector at the
BamHI and EcoRI sites. The vectors were transformed
into Escherichia coli BL21. Expression of fusion pro-
teins were induced by 0.5–1mM of isopropyl-b-D-
thiogalactoside (IPTG) at 20 Ct o2 5  C overnight. The
puriﬁcation of GST fusion proteins was performed using
Glutathione Sepharose 4B (GE Healthcare) as the manu-
facturer’s instruction with slight modiﬁcation. The puriﬁ-
cation efﬁciency and protein concentration were identiﬁed
using silver staining as described previously (34). The
puriﬁed recombination proteins were stored at  80 C
for further in vitro protein acetylation assay. GST and
p53 (29) fusion protein were used as negative and
positive controls, respectively.
In vitro protein acetylation assay
The HAT domain of p300/CBP protein was purchased
from Upstate company (#14-418, Upstate). The protein
acetylation assay was performed as previously described
with slight modiﬁcation (30). In the standard assay, a 50ml
reaction mixture contained 20mg of puriﬁed GST fusion
protein, 0.5mg of HAT of p300/CBP protein, 4mgo f
acetyl-CoA (Ac-CoA) (Sigma) and 10mlo f5   HAT
assay buffer (250mM Tris–HCl, pH 8.0, 50% glycerol,
0.5mM EDTA, 5mM dithiothreitol). The contents were
mixed gently and placed in a 30 C shaking incubator for
4h. Fifty microliters of 2  protein loading buffer was
added into the reaction and boiled for 5min. The
reaction products were separated by SDS–PAGE and
immunoblotted with the acetylated-lysine antibody
(#9681, CST).
Reporter gene assay
Cells were transfected with the above-mentioned plasmids
using Lipofectamine 2000 (Invitrogen). Cell lysates were
prepared with the Dual Luciferase Reporter Assay Kit
(Promega) as the manufacturer’s instruction at 36–48h
post-transfection. The normal promoter plasmid
pGL3-NP was constructed by inserting part of the normal
p16
INK4A promoter (length of 658bp from transcriptional
origin) into pGL3-basic, and the mutant promoter plasmid
pGL3-MP was constructed by inserting part of the
mutated p16
INK4A promoter (point mutation at HBP1-
binding site: change gggggTaggggg to gggggAaggggg).
Changing T at position of  430bp to A results in the
HBP1 abortive binding to p16
INK4A promoter. The
Fireﬂy Luciferase activity measurements were normalized
to Renilla Luciferase activity for the same sample. The
luciferase assay was performed on three biological repli-
cates and each replicate was measured at least three times.
Senescence-associated-b-gal staining
Cells were washed twice with PBS, ﬁxed for 3–5min in 2%
formaldehyde/0.2% glutaraldehyde or 3% formaldehyde
at room temperature, and washed again with PBS. The
cells were then incubated overnight at 37 C without CO2
in fresh senescence-associated-beta-gal (SA-b-Gal) stain
solution (31) consisting of 1mg/ml 5-bromo-4-chloro-
3-indolyl b-D-galactopyranoside (X-Gal), 40mM citric
acid–sodium phosphate, pH 6.0, 5mM potassium ferro-
cyanide, 5mM potassium ferricyanide, 150mM NaCl and
2mM MgCl2. At least 300 cells were counted in randomly
chosen ﬁelds.
RESULTS
HBP1-induced p16
INK4A expression is enhanced by
TSA treatment
First, we found that HDAC inhibitor TSA increased
p16
INK4A mRNA and protein levels signiﬁcantly in a
dose-dependent manner in 2BS cells, but had no effect
on transcription factor HBP1 expression, as shown in
Figure 1A. As previously reported, HBP1 upregulated
p16
INK4A expression through targeting to the p16
INK4A
promoter (18). This role of HBP1 was enhanced by TSA
treatment (Figure 1B). TSA was not able to induce
p16
INK4A expression if HBP1 was knocked-down with
shRNA (Figure 1C). With senescence-associated
b-galactosidase staining (SA-b-gal staining), a senescence
biomarker, Figure 1D shows that both HBP1 and TSA
increased the percentage of cells for SA-b-gal staining.
Furthermore, HBP1-induced premature senescence was
enhanced by TSA treatment. All of the data indicate that
HBP1 induced p16
INK4A expression and that prema-
ture senescence was enhanced by TSA. TSA-induced
p16
INK4A expression depends on HBP1.
TSA enhances the transcriptional activity of HBP1
through increasing DNA binding of HBP1 to
the p16
INK4A promoter
Here, we asked whether TSA increased the transcriptional
activity of HBP1 on p16
INK4A. We performed overlap
PCR to construct a mutant promoter in the background
of the native p16
INK4A promoter (NP), designated as MP
(point mutation at position  430 in HBP1-binding site:
change T to A) (Figure 2A). 2BS cells were then trans-
fected with HBP1 and luciferase reporters with the native
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INK4A promoter (NP) or the mutant p16
INK4A
promoter (MP). In the luciferase assay, HBP1 failed to ac-
tivate MP, whereas it increased NP activity signiﬁcantly
as previously reported. The result indicates that the in-
tegrity of binding site is indispensible for HBP1 to
enhance p16
INK4A promoter activity in vivo. As shown in
Figure 2B, TSA also enhanced the activity of the p16
INK4A
promoter (NP), but it had no effect on MP, which indi-
cates that TSA-induced p16
INK4A expression needs
HBP1 binding. The transcriptional activity of p16
INK4A
promoter in TSA-treated cells was  10-fold higher than
that in control cells. Furthermore, TSA enhanced the tran-
scriptional activity of HBP1 on p16
INK4A (Figure 2C). But
TSA lost its transcriptional activation ability at the
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Figure 1. HBP1-induced p16
INK4A expression was enhanced by TSA treatment. (A) 2BS cells were treated with TSA at different concentration (0, 1,
2.5, 5mM) for 18h. The mRNA levels of p16
INK4A and HBP1 were determined by RT–PCR (left panel). The protein levels of HBP1 and p16
INK4A
were determined by western blot (right panel). (B) 2BS cells were stably infected with pITA-HBP1. After selection for 3 days, cells were treated with
TSA at 1mM for 18h. mRNA (left panel) and protein (right panel) were extracted for analysis. (C) 2BS cells were transfected with pHBP1shRNA or
pSuper.retro (as control). After selection for 3 days, cells were treated with TSA at 1mM for 18h. The left panel shows HBP1 knockdown efﬁciency
determined by RT–PCR and the right panel shows the protein level of p16
INK4A measured by western blot. (D) Young 2BS cells (PD20) were
transfected with pITA-HBP1. After selected with puromycin for 3 days, cells were treated with TSA. Then the cells were stained for SA-b-gal (left
panel). The percentage of cells positive for SA-b-gal in 2BS cells is shown in right panel. At least 300 cells were counted for each sample.
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INK4A promoter when HBP1 was knocked-down with
shRNA (Figure 2D), which means that TSA-induced
p16
INK4A expression requires HBP1. We have reported
that HBP1 regulates p16
INK4A expression through
binding to the p16
INK4A promoter. In this study, we
used the ChIP assay to test the change of DNA binding
of HBP1 to the p16
INK4A promoter after TSA treatment.
As shown in Figure 2E, the binding increased after TSA
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Figure 2. TSA increased HBP1 transactivation on p16
INK4A by enhancing the DNA binding of HBP1 to the promoter region of p16
INK4A.( A) The
integrity of binding site is indispensible for HBP1 enhancing p16
INK4A promoter. Schematic diagrams of the native p16
INK4A promoter (NP) and its
mutant promoter (MP) (left panel). The mutant promoter was constructed by changing one point (T to A) in HBP1-binding site in the background
of native p16
INK4A promoter. Luciferase assay was performed in cells transfected with NP, or MP and HBP1 to test p16
INK4A mutant promoter
(right panel). (B) HBP1-binding site is required for activating TSA-induced p16
INK4A expression. Thirty hours after transfection with either
pGL3-NP or pGL3-MP, 2BS cells were treated with TSA at 1mM for 18h. Relative luciferase activity was measured after TSA treatment. (C)
The transactivation of HBP1 on p16
INK4A is enhanced by TSA. Thirty hours after transfection with HBP1, cells were treated with TSA at 1mM for
18h. Then the cells were harvested for luciferase assay. (D) TSA loses its transactivation ability at the p16
INK4A promoter when HBP1 was
knocked-down with shRNA. Thirty hours after transfection with HBP1shRNA, cells were treated with TSA at 1mM for 18h. Then the cells
were harvested for luciferase assay. (E) TSA enhances the DNA binding of HBP1 to the promoter region of p16
INK4A in vivo. ChIP assay with
antibody against HBP1 was performed in 2BS cells with or without TSA treatment at 1mM for 18h. Lanes with input chromatin were positive
controls (lanes 2, 6). Lanes without chromatin or GAPDH antibody were used for negative controls (lanes 1, 3, 5, 7). At the bottom, anti-HBP1
western immunoblotting (IB) for HBP1 protein expression is shown.
Nucleic AcidsResearch, 2012, Vol.40,No. 3 985treatment, consistent with previous result showing that
p16
INK4A expression increased in TSA-treated cells. All
the results indicate that TSA enhances the transcriptional
activity of HBP1 through increasing DNA binding of
HBP1 to the p16
INK4A promoter.
HBP1 is an acetylated protein
Figure 1A shows that HBP1 mRNA level was not obvi-
ously changed upon TSA treatment in 2BS cells. However,
TSA was not able to induce p16
INK4A expression if HBP1
was knocked-down with shRNA (Figure 1C). The data
imply that a modiﬁcation in HBP1 induced by TSA may
lead to HBP1 transcriptional activation of p16
INK4A.T o
determine whether HBP1 is acetylated in the cells, 2BS
cells were transfected with a HA-HBP1 expression
vector and then treated with TSA. Subsequently, an
acetyl-lysine antibody was used for detecting HBP1 acetyl-
ation in the TSA-treated 2BS cells. By performing IP with
anti-HA and then probing with acetyl-lysine antibody, or
IP with acetyl-lysine antibody and then probing with
anti-HA, exogenous HBP1 acetylation was conﬁrmed in
the TSA-treated cells (Figure 3A). In addition, we also
tested the endogenous HBP1 acetylation. As shown in
Figure 3B, with HBP1 antibody to substitute for
anti-HA, by performing IP with anti-HBP1 and then
probing with acetyl-lysine antibody, endogenous HBP1
was also acetylated within cells. In summary, the data
allowed us to conclude that HBP1 was indeed acetylated
within the cells upon TSA treatment.
HBP1 interacts with p300/CBP and recruits p300/CBP
onto the p16
INK4A promoter
Given that HBP1 is an acetylated protein, then which
enzyme can acetylate it? To answer the question, we
tested the physical association between HBP1 and p300/
CBP or PCAF by co-immunoprecipitation analysis with
nuclear extracts of HEK293T cells ectopically expressing
HA-tagged full-length HBP1 since p300/CBP and PCAF
have been shown to acetylate transcription factors in
addition to their histone substrates (36). Western blot
analysis showed the presence of HA-HBP1 in the IP of
p300 or CBP but not that of PCAF. The reciprocal
analysis also showed the presence of p300 and CBP in
the HA-HBP1 IP (Figure 4A). As shown in Figure 4B,
we further conﬁrmed this interaction between endogenous
HBP1 and p300/CBP. When p300/CBP knockdown with
siRNA, HBP1 cannot be acetylated even though cells were
treated with TSA, which indicates that p300/CBP acetyl-
ates HBP1 through directly binding (Figure 4C).
Transcriptional activation by a transcription factor in-
volves the recruitment of various coactivators to the spe-
ciﬁc binding site on DNA, which then directly or
indirectly interact with components of the basal transcrip-
tion machinery. As p300/CBP is known to function as a
coactivator connecting sequence-speciﬁc transcription
factors with the basal transcription machinery, it is pos-
sible that HBP1 could recruit p300/CBP onto p16
INK4A
promoter. This hypothesis was supported by the ChIP
assay results shown in Figure 4D, in which p300/CBP,
but not PCAF, were recruited to the p16
INK4A
promoter. The recruitment of p300/CBP is abolished in
the absence of HBP1. All of the data indicates that
HBP1 interacts with p300/CBP and is acetylated by
p300/CBP. As shown in Figure 4E, TSA lost its transac-
tivation on p16
INK4A when p300/CBP are knocked-down,
which means that the function of TSA is to inhibit the
HDAC activity and allow the p300/CBP-dependent
acetylation to become dominant.
HBP1-induced premature senescence is repressed by
HDAC4
HBP1 and TSA cooperate to induce senescence, meaning
that, despite the acetylation of HBP1 by p300/CBP, a
HDAC permanently deacetylates HBP1 and prevents the
induction of senescence. It is very important to identify the
HDAC involved. We previously reported that HDAC4, a
class II HDAC binds with HBP1 within a region of amino
acids 220–250 (35). Our next work is to test whether
HDAC4 inﬂuences HBP1-induced premature senescence.
As shown in Figure 5, with western blot and SA-b-gal
staining assay, exogenous HDAC4 represses HBP1-
induced p16
INK4A expression, thus represses HBP1-induced
premature senescence. While HDAC4 knockdown highly
enhances HBP1-induced p16
INK4A expression, thus
enhances HBP1-induced premature senescence.
Wild-type HBP1, Repression domain and P domain of
HBP1 are acetylated by p300/CBP in vitro
Acetylation has been shown to regulate the activity of
many transcription factors, including sequence-speciﬁc
DNA-binding factor p53 (17). To determine whether
p300/CBP acetylate HBP1, we performed an in vitro
acetylation reaction using GST-tagged HAT (a catalytic
subunit of p300/CBP) puriﬁed from transformed E. coli as
IP: HBP1(HA) 
Acetyl-lysine
-TSA      +TSA 
HBP1(HA)
A
IP: HBP1 
Acetyl-lysine
-TSA      +TSA 
HBP1
B
HBP1(HA)
IP: Acetyl-lysine
-TSA     +TSA 
Acetyl-lysine
Figure 3. HBP1 was acetylated within the cells. (A) Exogenous HBP1
was acetylated within the cells. 2BS cells transfected with
HBP1(HA-tagged) were treated with TSA at 1mM for 18h. IP assay
was carried out by using HA antibody and followed by western blot
with acetyl-lysine antibody (left). IP assay was carried out by using
acetyl-lysine antibody and followed by western blot with HA
antibody (right). (B) Endogenous HBP1 was acetylated within the
cells. 2BS cells were treated with TSA at 1mM for 18h. IP assay was
carried out by using HBP1 antibody and followed by western blot with
acetyl-lysine antibody.
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larly puriﬁed from E. coli as GST fusion proteins and used
as substrates. As shown in Figure 6A, GST-HAT efﬁ-
ciently acetylated GST-HBP1, as well as GST-p53. GST
alone was not acetylated by HAT, showing that the
in vitro acetylation was speciﬁc to HBP1. Our next step
was to identify the speciﬁc lysines acetylated by p300/
CBP. As the HBP1 amino acid sequence contains 31
lysines, our strategy was to design three mutants, contain-
ing either the C-terminal DNA-binding domain (HMG
box binding), middle region (the Repression domain), or
the regions outside of the HMG box binding and the
Repression domains (designated as P domain). In
addition, we designed two deletion mutants lacking either
the HMG box (designated as DelHMG) or Repression
domain (designated as DelRepression) (Figure 6B) for
further conﬁrmation. We then performed the same
GST-IP/anti-acetyl-lysine western blot with each HBP1
mutants as was done with wild-type HBP1 as shown in
Figure 6A. All of the mutants were efﬁciently over-
expressed and puriﬁed in cells (Figure 6C). Acetylation
was still detectable in the Repression domain and P
domain as well as DelHMG and DelRepression
mutants, whereas acetylation in the HMG box was absent
(Figure 6D), suggesting that the Repression domain and
the P domain contain the acetylation target. As the
Repression domain and the P domain contain 11 and 8
lysines respectively, we produced several more deletion
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Figure 4. HBP1 interacted with p300/CBP and recruits p300/CBP onto the promoter of p16
INK4A.( A) Exogenous HBP1 interacts with p300/CBP.
HEK293T cells transfected with HA-HBP1 were subjected to immunoprecipitation with anti-HA antibody. Immunoprecipitated complexes were used
for western blot analysis with anti- p300, anti-CBP or anti-PCAF antibody, respectively (left). The interaction of HBP1 and p300/CBP was further
conﬁrmed by reciprocal analysis. IP was performed with anti-p300, anti-CBP or anti-PCAF antibody respectively and followed with western blot
with anti-HA antibody (right). The bottom lanes were for determining IP efﬁciency. (B) Endogenous HBP1 interacted with p300/CBP. HEK293T
cells were subjected to immunoprecipitation with anti-HBP1 antibody. Immunoprecipitated complexes were used for western blot analysis with
anti-p300, anti-CBP or anti-PCAF antibody respectively. The bottom lanes were for determining IP efﬁciency. (C) Endogenous HBP1 cannot be
acetylated when p300/CBP knockdown. HEK293T cells were transfected with p300siRNA and CBPsiRNA. The protein levels of p300 and CBP were
determined by western blot (left panel). Then the cells were subjected to immunoprecipitation with anti-HBP1 antibody with or without TSA
treatment. Immunoprecipitated complexes were used for western blot analysis with acetyl-lysine antibody (Right panel). (D) HBP1 is required for
p300/CBP recruitment onto p16
INK4A promoter when TSA was applied. HEK293T cells were transfected with HBP1shRNA. The protein level of
HBP1 was determined by western blot (left panel). ChIP assay with anti-p300, anti-CBP and anti-PCAF antibody was performed in HEK293T cells
after treated with TSA at 2.5mM for 18h with or without HBP1shRNA transfection. (E) TSA loses its transactivation ability at the p16
INK4A
promoter when p300/CBP knockdown. Thirty hours after transfection with p300/CBP siRNA, cells were treated with TSA at 2.5mM for 18h. Then
the cells were harvested for luciferase assay.
Nucleic AcidsResearch, 2012, Vol.40,No. 3 987mutants. As shown in Figure 6B, the Repression domain
was divided into four short fragments (R1, R2, R3, R4),
and the P domain was divided into three short fragments
(P1, P2, P3). Then we performed the same GST-IP/anti-
acetyl-lysine western blot with each HBP1 mutant as was
done previously with wild-type HBP1. Acetylation was
still detectable in R3, P2 and P3 (Figure 6D), suggesting
that these three domains contain the acetylation targets.
The K297, K305, K307 of the Repression domain
and K171, K419 of the P domain are acetylated
by p300/CBP in vitro
There are only three lysines in R3, three lysines in P2, and
two lysines in P3. To determine which lysine can be
acetylated by p300/CBP, we performed overlap-PCR to
mutate each lysine to arginine, individually as well as sim-
ultaneously (Figure 7A). All the mutants were efﬁciently
overexpressed in cells (Figure 7B). We then performed the
GST-IP/acetyl-lysine western blot with each mutant. We
found that K297, K305, K307 in the Repression domain
and K171, K419 in the P domain can be acetylated by
p300/CBP (Figure 7C), suggesting p300/CBP targets
speciﬁc lysines on HBP1 for acetylation.
Acetylation of HBP1 at K419 is required for
HBP1-induced premature senescence
Given that acetylation of a transcription factor often has
an effect on its transcriptional activity, we decided to in-
vestigate the ability of the lysine mutant HBP1 in act-
ivating p16
INK4A. Cotransfection of a p16
INK4A
promoter-luciferase construct with wild-type HBP1 into
HEK293T cells resulted in an  4-fold increase in the ac-
tivation of the reporter (Figure 8A). Acetylation-deﬁcient
mutant K297/305/307R of the Repression domain main-
tained same result after cotransfection with p16
INK4A
promoter–luciferase construct and still responded to
TSA, suggesting that acetylation of Repression domain
has no effect on HBP1 transactivation on p16
INK4A.
Furthermore, we tested the binding of the mutant and
p300/CBP with IP. As shown in Figure 8B, exogenous
K297/305/307R (HA-tag) still binds to p300/CBP, but
not PCAF. The result was consistent with our previous
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Figure 5. HDAC4 represses HBP1 ability to induce senescence. (A) 2BS cells were stably infected with pITA-HBP1. After selection for 3 days, cells
were transfected with pITA-HDAC4. The protein levels of HBP1 (HA), HDAC4 (Flag) and p16
INK4A were measured by western blot (left panel).
Then the cells were stained for SA-b-gal. The percentage of cells positive for SA-b-gal in 2BS cells is shown in right panel. At least 300 cells were
counted for each sample. (B) 2BS cells were stably infected with pITA-HBP1. After selection for 3 days, cells were transfected with
pSR-HDAC4shRNA. The protein levels of HBP1 (HA), HDAC4 and p16
INK4A were measured by western blot (left panel). Then the cells were
stained for SA-b-gal. The percentage of cells positive for SA-b-gal in 2BS cells is shown in right panel. At least 300 cells were counted for each
sample.
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C
D
B
Figure 6. Wild-type HBP1 and mutants were acetylated by HAT of p300/CBP in vitro. (A) HBP1 was acetylated by HAT in vitro. At the top,
puriﬁed GST-tagged HBP1 protein was incubated with HAT in the presence of Ac-CoA. The reaction products were separated by SDS–PAGE and
immunoblotted with the acetyl-lysine antibody. At the bottom, the same nitrocellulose membrane as used in the in vitro acetylation assay described
above was stripped and immunoblotted with anti-GST antibody. GST and GST-tagged p53 proteins were used for negative and positive controls,
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(continued)data that the Repression domain is not required for
HBP1-induced p16
INK4A expression. K171R of the P
domain had no effect on HBP1 transactivation either
(Figure 8C). However, HBP1-K419R was only able to
activate the reporter to  30% level of the wild-type
HBP1. The cells transfected with K419R or K171/419R
have almost same response to TSA compared with the
control cells. As shown in Figure 8D, we found that
overexpression of the wild-type HBP1 resulted in an
 10-fold induction of p16
INK4A protein. Overexpression
of mutant K171R resulted in almost the same level of
p16
INK4A protein induction as that of wild-type HBP1,
Figure 6. Continued
respectively. (B) Schematic diagram of wild-type HBP1 and associated mutants. (C) Expression of wild-type HBP1 and associated mutants proteins
in E. coli. GST-tagged proteins were immunoprecipited with GST, then ran on SDS–PAGE and stained with silver. (D) HBP1 and some mutants
(Repression domain, P domain) were acetylated by HAT in vitro. GST-tagged proteins from experiments shown in (B) were incubated with Ac-CoA
and HAT in 30 C for 4h. The reaction products were separated by SDS–PAGE and immunoblotted with the acetyl-lysine antibody. GST was as
loading control.
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Figure 8. The acetylation of HBP1 at K419 was indispensible for HBP1-induced premature senescence. (A) HBP1 acetylation at K297/305/307 was not
required for transactivation on p16
INK4A. HEK293T cells were cotransfected with HBP1 or point mutants K297/305/307R and pGL3-p16
INK4A
promoter for 48h. After transfection, cells were treated with TSA at 2.5mM for 18h. Then the cells were harvested for luciferase assay. (B) K297/
305/307 was not required for interaction of HBP1 and p300/CBP. The whole cell extracts were subjected to immunoprecipitation with anti-HA antibody.
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(continued)whereas overexpressing K419R or K171/419R produced
no induction compared with control vector. These results
suggest that acetylation of HBP1 at K419 is important
for its transactivation on p16
INK4A. Furthermore, we
tested the inﬂuence of acetylation on the binding of
HBP1 onto p16
INK4A promoter with the ChIP assay. As
shown in Figure 8E, the binding of HBP1 onto p16
INK4A
promoter was abrogated as HBP1 was mutated at K419R
or K171R/419R, while no difference was observed when
only mutated at K171R. This demonstrates that HBP1
acetylation at K419 is required for the binding of HBP1
onto the p16
INK4A promoter. To further detect the func-
tional importance of K419 acetylation in transcriptional
activation, we transfected wild-type and mutant HBP1
into human normal ﬁbroblasts 2BS cells. After 3days se-
lection, we treated the cells with or without TSA, then
ﬁxed the cells and stained with SA-b-gal. As shown in
Figure 8F, both wild-type HBP1 and K171R increased
the percentage of cells for SA-b-gal staining, whereas
K419R and K171/419R did not change the percentage.
The cells transfected with K419R or K171/419R have
almost same response to TSA compared with the control
cells, suggesting that acetylation of HBP1 at K419 is
required for HBP1-induced premature senescence.
All these data indicate that acetylation of HBP1 at K419
regulates HBP1-induced premature senescence through en-
hancing the binding of HBP1 to the p16
INK4A promoter.
The cells transfected with K419R are still slightly
responsive to TSA because of endogenous HBP1. To
further investigate the impact of acetylation on HBP1-
induced transactivation on p16
INK4A and premature
senescence, we induced p300/CBPsiRNA into the cells
transfected with wild-type HBP1 or K419R. As shown
in Figure 8G, 8H, with luciferase assay and SA-b-gal
staining, the cells transfected with either wild-type HBP1
or K419R are not responsive to TSA, suggesting that
acetylation at K419 is essential for the HBP1 functions
in the activation of p16
INK4A and for the activation of
premature senescence.
DISCUSSION
Histone acetylation regulates many cellular processes,
including nucleosome assembly, chromatin compac-
tion, heterochromatin formation and gene transcription.
Hyperacetylated histones have long been known to asso-
ciate with activated genes, and some studies further suggest
a causal relationship between histone acetylation and gene
activation. It is thought that addition of acetyl groups
to the lysine residues of histone tails facilitates access of
transcription factors to DNA by disrupting higher-order
packaging of the chromatin and by recruiting bromo-
domain factors, which recognize acetyl-lysine motifs
(32,33). The bromodomain, found in chromatin-
associated proteins and histone acetyltransferase, func-
tions as the sole protein module known to bind
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Figure 8. Continued
Immunoprecipitated complexes were used for western blot analysis with anti-p300, anti-CBP or anti-PCAF antibody respectively. The bottom lanes
were for determining IP efﬁciency. The interaction of HBP1 and p300/CBP was further conﬁrmed by reciprocal analysis. (C) HBP1 acetylation at
K419 was required for transactivation on p16
INK4A. HEK293T cells were transfected with pGL3-p16
INK4A promoter and HBP1 or mutants for 48h.
After transfection, cells were treated with TSA at 2.5mM for 18h. Then the cells were harvested for luciferase assay. (D) HBP1 acetylation at K419
was required for HBP1-induced p16
INK4A expression. p16
INK4A protein level in 2BS cells transfected with HBP1 and mutants for 5-7 days was
determined by western blot. (E) HBP1 acetylation at K419 was required for the binding of HBP1 onto p16
INK4A promoter. ChIP assay with antibody
against HA was performed in HEK293T cells transfected with HBP1 or mutants. (F) HBP1 acetylation at K419 is required for HBP1-induced
premature senescence. 2BS cells transfected with HBP1 or mutants with or without TSA treatment were stained for SA-b-gal (up panel). The
percentage of cells positive for SA-b-gal is shown in low panel. At least 300 cells were counted for each sample. (G) p300/CBP knockdown attenuates
the HBP1-induced p16
INK4A gene activity. 2BS cells were stably infected with pITA-HBP1. After selection for 3 days, cells were transfected with
p300/CBP siRNA and pGL3-p16
INK4A promoter. After transfection, cells were treated with TSA at 1mM for 18h. Then the cells were harvested for
luciferase assay. (H) p300/CBP knockdown attenuates the HBP1-induced senescence. 2BS cells were stably infected with pITA-HBP1. After selection
for 3 days, cells were transfected with p300/CBP siRNA. After transfection, cells were treated with TSA at 1mM for 18h. Then the cells were stained
for SA-b-gal.
992 Nucleic Acids Research, 2012,Vol. 40,No. 3acetyl-lysine motifs. Recently, acetylation of transcription
factors has been drawing more attention. Acetylation has
been shown to be a key regulatory mechanism for the
activity of many transcription factors (24–26). Although
several other intensely studied transcription factors have
been shown to be acetylated by p300 (19–22), the acetyl-
ation of HBP1 has not been reported previously. We had
reported that HBP1 participates in Ras-induced prema-
ture senescence through targeting p16
INK4A, but whether
the acetylation of HBP1 impacted p16
INK4A expression
remained unknown. In this study, we used the HDAC
inhibitor TSA to treat cells, and found that TSA led to
increased p16
INK4A expression. Moreover, TSA-induced
p16
INK4A expression depended on HBP1 (Figure 1C), sug-
gesting that HBP1 is a key regulator for TSA-induced
p16
INK4A expression. Although no change in the HBP1
mRNA level was detected after TSA treatment, the
p16
INK4A mRNA and protein levels increased signiﬁcantly
in 2BS cells. We proposed that post-translational modiﬁ-
cations of HBP1, especially acetylation, might play a role
in regulating p16
INK4A expression. This hypothesis was
supported by evidence that TSA enhances the transcrip-
tional activity of HBP1 through increased DNA binding
of HBP1 onto p16
INK4A promoter. Furthermore, we
found that HBP1 was acetylated within the cells, as after
immunoprecipitation of HA-HBP1 from HEK293T cells,
we could detect HBP1 acetylation with an acetyl-lysine
antibody.
Since HBP1 is an acetylated protein, which acetyl-
transferase can acetylate it? With IP-western blot and
ChIP assay, we identiﬁed that HBP1 interacted with
p300/CBP and recruited p300/CBP onto p16
INK4A
promoter. In addition, HBP1 was acetylated by p300/
CBP in vitro. By making deletions and site mutations of
full-length HBP1, we identiﬁed the acetylated lysines at
Lys-297, 305, 307 in the Repression domain and
Lys-171, 419 in the P domain. All ﬁve lysines were acety-
lated by p300/CBP in vitro, and they were not acetylated
when mutated to arginine, which indicates that these are
speciﬁc acetylation sites.
The acetylation of HBP1 appears to be important in
HBP1-mediated transactivation of p16
INK4A, as mutation
of Lys-419 in HBP1 sequence resulted in decreased acti-
vation of a p16
INK4A reporter and signiﬁcantly blocked
the HBP1-mediated induction of the p16
INK4A protein.
Acetylation of HBP1 at Lys-419 is also indispensable for
HBP1-induced premature senescence because HBP1 lost
the ability to induce senescence when Lys-419 was
mutated to arginine. However, acetylation of the other
lysines (Lys-297, 305, 307 and Lys-171) had no effect on
HBP1-mediated transactivation on p16
INK4A. The results
are in concert with our previous report that the Repression
domain (Lys-297, 305, 307 are in the Repression domain)
is not required for HBP1-induced p16
INK4A expression.
HBP1 is a dual transcription factor. It has many targets:
Cyclin D1, c-myc, p47 phox, and p16
INK4A, etc. The iden-
tiﬁcation of the diverse set of targets, either being
activated or repressed by HBP1, suggests that HBP1 has
multiple mechanisms for affecting G1 progression and for
suppressing oncogenic pathways. Although it was known
that the Repression domain of HBP1 is required for its
suppression function, the underlying mechanism for such
function was unclear. Our results suggest that acetylation
of Repression domain may be important for HBP1-
induced repression. We identiﬁed that HDAC4 represses
HBP1-induced p16
INK4A expression, thus represses
HBP1-induced premature senescence. While HDAC4
knockdown highly enhances HBP1-induced p16
INK4A ex-
pression, thus enhances HBP1-induced premature senes-
cence. The function of HDAC4 may be through directly
binding to the Repression domain, because there is
binding site within the domain. More experiments are
needed to test this hypothesis and to answer the question
of whether HBP1 interacts with HDACs directly or
possibly through other corepressors.
In this study, we observed that HBP1 interacted with,
and was acetylated by, the HAT protein p300/CBP. This
observation is physiologically relevant, as we found that
HBP1 is acetylated in vivo as well. Furthermore, we found
that HBP1 recruited p300/CBP onto p16
INK4A promoter
and enhanced HBP1 transactivation on p16
INK4A. The re-
cruitment of p300/CBP is abolished in the absence of
HBP1. Our data indicate that HBP1 interacts with p300/
CBP and is acetylated by p300/CBP. The function of TSA
is to inhibit the HDAC activity and allow the p300/
CBP-dependent acetylation to become dominant.
Therefore, TSA would lose its transactivation on
p16
INK4A when p300/CBP are knocked-down.
Actually, HBP1 has dual function in transcription.
Most of our previous works focused on its transcriptional
repression and regarded HBP1 as a novel transcriptional
repressor in differentiation (1–3,6,9). Only several papers
reported that HBP1 is a transcriptional activator in
myeloid differentiation and transformation (10,18). The
acetylation of HBP1 at Lys-419 was required for transac-
tivation of p16
INK4A and for the activation of premature
senescence. Might K419 acetylation (or non-acetylation)
determine whether HBP1 functions as an activator or
repressor? Is K419R mutant functional for transcriptional
repression? To answer the questions, we cotransfected
with a Wnt promoter-luciferase construct and wild-type
HBP1 or K419R mutant into HEK293T cells. With
luciferase assay, we found that both HBP1 and K419R
repressed activation of the reporter (data not shown).
The result indicates that the acetylation of K419 does
not switch HBP1 from a transcriptional repressor to a
transcriptional activator, except for its transactivation
for p16
INK4A. Other modiﬁcations or co-repressors
might be involved.
Our previous study linked HBP1 with p16
INK4A. The
present study describes that acetylation by p300/CBP
enhances the effect of HBP1 on the regulation of
p16
INK4A, thereby impacts on the process of replicative
senescence. The expression of p16
INK4A in replicative sen-
escence is hugely elevated. Although the mechanisms
underlying is not fully understood, both transcriptional
and post-transcriptional regulation are considered import-
ant. Factors reported to be involved in the transcriptional
regulation of p16
INK4A include CREG1, SP1 and HBP1,
etc. The contribution of HBP1- p16
INK4A regulatory
process to the elevation of p16
INK4A in replicative senes-
cence is not easy to be evaluated. However, our study
Nucleic AcidsResearch, 2012, Vol.40,No. 3 993suggests that the HBP1- p16
INK4A regulatory process is at
least partly responsible for the regulation of p16
INK4A.
Overall, the molecular mechanisms of HBP1-mediated
gene expression will have important implications within
several ﬁelds, including senescence biology, cancer
biology and stem cell biology.
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